Shopping Cart
- Remove All
- Your shopping cart is currently empty
SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor targeting the 3C-like protease (3CLpro), with potent inhibitory activity (IC50: 3.8 nM) and 9.0% oral bioavailability (BA), used in COVID-19 research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 8-10 weeks | |
50 mg | $1,980 | 8-10 weeks | |
100 mg | $2,500 | 8-10 weeks |
Description | SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor targeting the 3C-like protease (3CLpro), with potent inhibitory activity (IC50: 3.8 nM) and 9.0% oral bioavailability (BA), used in COVID-19 research [1]. |
In vitro | SARS-CoV-2 3CLpro-IN-5 demonstrates inhibitory activity against 3CL protease with an IC50 of 3.8 nM [1], and antiviral effects against SARS-CoV-2 variants (Alpha, Delta, Omicron BA.1, BA.2) in 293TAT cells, with EC50 values of 13.8 nM, 7.57 nM, 9.01 nM, and 17.1 nM, respectively [1]. It also shows activity against other coronaviruses: SARS-CoV (EC50 59.3 nM), MERS-CoV in 293TDPP4 cells (EC50 4.72 nM), and HCoV-OC43 (EC50 1.67 nM) [1]. |
In vivo | SARS-CoV-2 3CLpro-IN-5, when administered orally or intravenously at dosages of 10 or 100 mg/kg, exhibits potent antiviral effects and possesses advantageous pharmacokinetic properties [1]. |
Molecular Weight | 497.92 |
Formula | C22H26ClF2N5O4 |
Cas No. | 2913186-57-7 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.